Hyperthermia: A Potential Game-Changer in the Management of Cancers in Low-Middle-Income Group Countries

Loco-regional hyperthermia at 40-44 °C is a multifaceted therapeutic modality with the distinct triple advantage of being a potent radiosensitizer, a chemosensitizer and an immunomodulator. Risk difference estimates from pairwise meta-analysis have shown that the local tumour control could be improv...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-01, Vol.14 (2), p.315
Main Authors: Datta, Niloy R, Jain, Bharati M, Mathi, Zatin, Datta, Sneha, Johari, Satyendra, Singh, Ashok R, Kalbande, Pallavi, Kale, Pournima, Shivkumar, Vitaladevuni, Bodis, Stephan
Format: Article
Language:English
Subjects:
Breast cancer
Cancer therapies
Cervical cancer
Cervix
Chemoradiotherapy
Chemotherapy
Clinical outcomes
Clinical trials
DNA damage
DNA repair
Drug dosages
Fever
Head & neck cancer
Heat
Hyperthermia
Immunomodulation
Meta-analysis
Physiology
Radiation therapy
Radiosensitizers
Review
Tumors
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Loco-regional hyperthermia at 40-44 °C is a multifaceted therapeutic modality with the distinct triple advantage of being a potent radiosensitizer, a chemosensitizer and an immunomodulator. Risk difference estimates from pairwise meta-analysis have shown that the local tumour control could be improved by 22.3% ( < 0.001), 22.1% ( < 0.001) and 25.5% ( < 0.001) in recurrent breast cancers, locally advanced cervix cancer (LACC) and locally advanced head and neck cancers, respectively by adding hyperthermia to radiotherapy over radiotherapy alone. Furthermore, thermochemoradiotherapy in LACC have shown to reduce the local failure rates by 10.1% ( = 0.03) and decrease deaths by 5.6% (95% CI: 0.6-11.8%) over chemoradiotherapy alone. As around one-third of the cancer cases in low-middle-income group countries belong to breast, cervix and head and neck regions, hyperthermia could be a potential game-changer and expected to augment the clinical outcomes of these patients in conjunction with radiotherapy and/or chemotherapy. Further, hyperthermia could also be a cost-effective therapeutic modality as the capital costs for setting up a hyperthermia facility is relatively low. Thus, the positive outcomes evident from various phase III randomized trials and meta-analysis with thermoradiotherapy or thermochemoradiotherapy justifies the integration of hyperthermia in the therapeutic armamentarium of clinical management of cancer, especially in low-middle-income group countries.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14020315